CALGARY —
A class-action lawsuit filed in Calgary against cannabis companies claims the THC and CBD levels in their medicinal and recreational cannabis products differed from what was represented on packaging.

According to the statement of claim filed at the Judicial Centre of Calgary on Tuesday, June 16, the companies allegedly sold cannabis products to Canadian consumers with drastically different THC (tetrahydrocannabinol) or CBD (cannabidiol) levels than advertised on the label.

The defendants named in the lawsuit are:

• Aurora Cannabis Inc.
• Aurora Cannabis Enterprises Inc.
• AuroraCo.
• Aleafiaco
• Aleafia Health Inc.
• Emblem Cannabis Corp.
• Hexo Corp.
• HexoCo
• Cronos Group Inc.
• Cronosco
• Tilray Canada Ltd.
• Organigram Holdings Inc.
• OrganigramCo
• MediPharm Labs Corp.
• MediPharmCo

The document indicates that THC and CBD levels were found to be significantly higher than indicated in some products while others may have had significantly lower levels as a result of absorption or degradation due to the use of plastic bottles.

The lawsuit is seeking $500 million in compensation for Canadians who purchased medicinal cannabis products between now and June 16, 2010 as well as Canadians who legally purchased cannabis for recreational purposes since Oct. 17, 2018.

Lisa Marie Langevin is named as the plaintiff representing the class-action. The Calgary woman claims to have purchased a cannabis oil from a…